We are live on ! Find out more
ATRC icon

AtriCure

213 hedge funds and large institutions have $2.98B invested in AtriCure in 2021 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 69 increasing their positions, 84 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more call options, than puts

Call options by funds: $1.87M | Put options by funds: $1.51M

18% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 22

0% more funds holding

Funds holding: 212213 (+1)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

2.6% less ownership

Funds ownership: 97.11%94.51% (-2.6%)

15% less capital invested

Capital invested by funds: $3.49B → $2.98B (-$507M)

18% less repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 84

Holders
213
Holders Change
+1
Holders Change %
+0.47%
% of All Funds
3.73%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
26
Increased
69
Reduced
84
Closed
22
Calls
$1.87M
Puts
$1.51M
Net Calls
+$361K
Net Calls Change
-$1.42M

ATRC Hedge Fund Activity: Q3 2021 in Review

213 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q3 2021, worth a combined $2.98B — down 15% from $3.49B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ATRC positions and 22 closed out — a net gain of 4 holders — while 69 added to existing stakes and 84 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $24.3M. The largest seller was Fidelity Investments, cutting an estimated $46.9M.

  • 213 institutional investors held AtriCure (ATRC) as of Q3 2021, up from 212 in Q2 2021.
  • Funds reported $2.98B of AtriCure stock for Q3 2021, down 15% quarter-over-quarter.
  • 26 funds opened new AtriCure positions in Q3 2021 and 22 closed out, a net change of +4 holders.
  • The largest AtriCure buyer in Q3 2021 was Balyasny Asset Management, an estimated $24.3M added.
  • The largest AtriCure seller in Q3 2021 was Fidelity Investments, an estimated $46.9M sold.

Based on aggregated 13F filings for Q3 2021.